-
DE30 descends into 16,000-point region
-
Beauty/luxury sector under pressure from China and Compagnie Financière Richemont results
-
Nordea's results keep banks afloat
-
Successful testing of Argenx's innovative drug lifts its shares 28% higher
The mood in the markets during this week's first trading session is relatively negative. Europe is seeing fairly strong declines, above all in France, where the CAC 40 is losing more than 1% due to sizable declines in luxury goods and cosmetics companies. Sentiment was pressured today by data from China, which came in below expectations, which, combined with a weak sales reading from Compagnie Financière Richemont in the US, spoiled sentiment in the beauty/luxury sector.
The mood in Europe during Monday's trading session is relatively negative. At the moment, the worst performers are the shares of fashion companies, which are losing on the wave of weak macro data from China and the worse-than-expected US sales results of Compagnie Financière Richemont (CFR.CH). Source: xStation 5
German DE30 futures are losing nearly 0.32% during today's session and are slipping to support levels around 16,000 points. Source: xStation 5
News:
The theme of the day during today's session is fashion companies, whose shares are losing sharply on the back of weak data from China and reported lower sales in the US by Compagnie Financière Richemont (CFR.CH), which owns the Cartier brand, among others.
Current quotations of selected fashion/luxury companies. Source: xStation 5
-
Chinese economic indicators showed growth in industrial production and retail sales below forecasts, while unemployment remained stable. China's Bureau of Statistics acknowledged that domestic economic conditions are improving, but cited complex global political and economic factors as challenges.
-
China's year-on-year (y/y) industrial production growth was 4.4%, higher than the 2.5% forecast and the 3.5% previously forecast.
-
China's unemployment rate remained at 5.2%, in line with the forecast and the previous rate.
-
China's year-on-year GDP growth was 6.3%, less than the 7.1% forecast but higher than the previous rate of 4.5%.
-
China's year-on-year retail sales growth was 3.1%, slightly below the forecast of 3.3% and well below the previous rate of 12.7%.
It is worth remembering that for all fashion companies, the Chinese market is one of the key markets.
Interestingly, however, the mood around Richemont was spoiled today by weak sales data from the US, which may signal that the conjuncture for the industry is also being challenged in the West.
Richemont's Q1 sales rose 14% to €5.32bn ($5.97bn), but organic growth of 19% was below expectations (20%) due to weak performance in the Americas (-4%).
Source: xStation 5
Nordea (NDA.FI), the largest bank in Scandinavia, reported a slightly higher than expected increase in operating profit in the second quarter, as rising interest rates outweighed negative foreign exchange differences.
The bank's operating profit rose year-on-year by 26% to €1.72 billion, against an average forecast of €1.70 billion in a survey by Refinitiv.
On the back of the surge, European banks managed to limit broad-market declines.
Belgian drugmaker Argenx (ARGX.BE) today communicated that its treatment with an antibody called Vyvgart has significantly delayed the progression of an autoimmune nerve disorder that causes loss of sensation and muscle strength in the arms and legs. The positive result - a 61% reduction in the risk of relapse compared to placebo. The company's shares are gaining nearly 28% in today's session.
The company's shares are climbing to their new historic highs today. Source: xStation 5
The largest percentage changes in individual companies of the DAX index. Source: Bloomberg
News from individual companies in the DAX index. Source: Bloomberg
Stock of the Week AMD: From second choice to core pillar of the AI infrastructure
US OPEN: Wall Street opens higher 🔼 Datadog and ARM in the spotlight 💥
Rheinmetall earninigs: Weak sales overshadow strong prospects
ARM Holdings Moves Closer to the Center of the AI Revolution. Strong Results Are No Longer Enough for the Market
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.